MedTrace Logo

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

NCT00131313 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2005-08-18

No results posted yet for this study

Summary

This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.

Conditions

Interventions

DRUG

Nipent, Cytoxan, Rituxan

Sponsors & Collaborators

  • Mena, Raul, M.D.

    collaborator INDIV

  • Pharmatech Oncology

    collaborator INDUSTRY

  • Astex Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • East Valley Hematology and Oncology Medical Group

    lead OTHER

Principal Investigators

  • Raul Mena, MD · East Valley Hematology and Oncology Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131313 on ClinicalTrials.gov